deltatrials
Completed PHASE3 INTERVENTIONAL 4-arm NCT01462435

Study of Diclofenac Capsules to Treat Pain Following Bunionectomy

A Phase 3, Randomized, Double-Blind, Multiple-Dose, Parallel-Group, Active- and Placebo-Controlled Study of Diclofenac [Test] Capsules for the Treatment of Acute Postoperative Pain After Bunionectomy

Sponsor: Iroko Pharmaceuticals, LLC

Conditions Other Acute Postoperative Pain
Interventions Celecoxib Diclofenac Test (lower dose) Diclofenac Test (upper dose) Placebo
Updated 6 times since 2017 Last updated: Jan 2, 2014 Started: Oct 31, 2011 Primary completion: Feb 29, 2012 Completion: Aug 31, 2012
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Other Acute Postoperative Pain, this trial is completed. The trial is conducted by Iroko Pharmaceuticals, LLC and has accumulated 6 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Oct 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Iroko Pharmaceuticals, LLC
Data source: Iroko Pharmaceuticals, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations